NANOBIOTIX : new translational data presented at ASTRO, NCI AND SITC'S Immunotherapy Workshop
(Thomson Reuters ONE) -
NANOBIOTIX: NEW TRANSLATIONAL DATA PRESENTED AT ASTRO, NCI AND SITC'S
IMMUNOTHERAPY WORKSHOP
* Translational data showing tumor immune activity and positive Tumor
Infiltrating Lymphocytes (TILs) in human and mouse model
* Confirmation of the ability to transform "cold" tumors into "hot" tumors and
that NBTXR3 treatment may have an impact on the tumor microenvironment
* Opening up of the potential for NBTXR3 to treat metastases
Paris, France and Cambridge, Massachusetts (USA), June 15, 2017 - NANOBIOTIX
(Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine
company pioneering new approaches to the treatment of cancer, today presented
new translational data at the "Immunotherapy workshop - Incorporating Radiation
Oncology into Immunotherapy" co-sponsored by the American Society of Radiation
Oncology (ASTRO), the National Cancer Institute (NCI) and the Society for
Immunotherapy of Cancer (SITC), that takes place from June 15 to 16, 2017 in
Bethesda, Maryland, USA.
Nanobiotix's lead product, NBTXR3, has a universal physical mode of action which
is designed for the local destruction of tumors. In addition to the physical
destruction of cancer cells, recently published data suggests that NBTXR3
generates immunogenic cell death which could trigger a specific immune response
to attack the tumor.
Many tumors exhibit little or no response to therapies targeting the immune
system and are considered "cold". The explanation for the lack of response in
its simplest form, is a lack of immunogenicity. The ability of NBTXR3 to
generate intratumoral immunogenic cell death (ICD) could be a key to
significantly increasing the number of patients who can benefit from the help of
their immune system to fight their cancer.
Today, Nanobiotix presented new translational data from its immuno-oncology
program.
"Hafnium oxide nanoparticle, a potent radiation enhancer for in situ cancer
vaccine" (June 15, 2017)
J. Galon(1), M. Laé(2), Z. Papai(3), P. Rochaix(4), L.C. Mangel(5), F.
Hermitte(6), Z. Sapi(7), M. Delannes(4), T. Tornoczky(5) , A. Vincent-
Salomon(2), V. Servois(2), H. Brisse(2), S. Paris(8), A. Pottier(8), and S.
Bonvalot(2)
(1)INSERM, Paris, France, (2)Institut Curie, Paris, France, (3)Magyar Honvedseg
Egeszsegugyi Kozpont, Budapest, Hungary, (4)Institut Universitaire du Cancer,
Toulouse, France, (5)Pecs University, Pecs, Hungary, (6)HalioDx, Marseille,
France, (7)Semmelweis University, Budapest, Hungary, (8)Nanobiotix, Paris,
France.
1. Human Soft Tissue Sarcoma (STS) patients data
In tumors of STS patients, a significant increase of T cells (CD3+, CD8+) and a
marked increase of dendritic cell (CD103+) infiltrates in post- versus pre-
treatment were observed for NBTXR3 plus radiotherapy arm, while no differences
were seen in the use of radiotherapy alone. These findings demonstrate the
ability of NBTXR3 to transform cold tumors (as Soft Tissue Sarcoma) in hot
tumors.
Large hemorrhagic zones have been found in tumor tissues treated with NBTXR3,
whereas tumors treated with radiotherapy alone did not show such patterns. This
finding shows that NBTXR3 could affect the tumor microenvironment and
potentially allow better infiltration of activated T Cells.
The upregulation of adaptive immunity gene expression between pre- and post-
treatment was pronounced for NBTXR3 plus radiotherapy - 72 genes only up-
regulated with the NBTXR3 treatment, showing enrichment of cytokine activity and
of the T cell receptor signaling pathway.
A number of upregulated genes correspond to existing or promising IO targets,
enabling a potential combination of NBTXR3 with therapeutic approaches, like
products targeting PD1, PDL1, CTLA4, etc. This data requires confirmation in
additional studies.
Asymmetrical volcano plot shows a trend toward the upregulation of panimmune
genes in post-treated tumors
of Soft Tissue Sarcoma patients.
The two charts compare the results of patients treated with radiotherapy alone
(left), with patients treated with radiotherapy plus NBTXR3 (right).
2. Mice model (CT26) data
In mice, the abscopal effect (i.e. an effect outside the scope of the localized
treatment) was evaluated. A tumor was implanted on each side of each mouse; one
of the tumors was treated with either NBTXR3 and radiotherapy, or radiotherapy
alone; while the other remained untreated. The treated tumors, both those that
received NBTXR3 and radiotherapy and those that received radiotherapy alone,
demonstrated volume shrinkage.
However, the study showed that only the use of NBTXR3 with radiotherapy resulted
in a control on the untreated tumors (abscopal effect). No effect was observed
in control groups and groups treated with radiation therapy alone.
In this model, NBTXR3 plus radiotherapy induces a noticeable increase of CD8+
and macrophages infiltrates in both tumors (treated and untreated). At the same
time, no effect was observed in cases where radiotherapy was used alone, when
compared to control groups (that received no irradiation). This demonstrates
that NBTXR3 plus radiotherapy can induce a marked systemic antitumor immune
response on distant and untreated tumors where radiotherapy alone couldn't.
3. Conclusion
Taken together, these non-clinical and preliminary clinical results confirm that
NBTXR3 plus radiotherapy could efficiently prime the adaptive antitumor immune
response, turning "cold" tumors in "hot" tumors. Additionally, these results
suggest that the physically-induced response and subsequent immune activation
triggered by the NBTXR3 treatment could be generic. NBTXR3 with radiotherapy
could transform these tumors into an effective in situ vaccine, opening up very
promising perspectives in the treatment of local cancer and metastases.
Tumor Immune Cell Infiltrates (TILs)
NBTXR3 competitive positioning in IO
Many IO combination strategies focus on 'priming' the tumor, which is now
becoming a prerequisite of turning a "cold" tumor into a "hot" tumor.
Compared to other modalities that could be used for priming the tumor, NBTXR3
could have a number of advantages: The physical and universal mode of action
that could be widely applied across oncology; the one-time local injection and
good fit within existing medical practice already used as a basis for cancer
treatment, as well as a very good chronic safety profile and well-established
manufacturing process.
The new clinical data and previous pre-clinical data indicate that NBTXR3 could
play a key role in oncology and could become a backbone in immuno-oncology.
***
About NANOBIOTIX: www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage
nanomedicine company pioneering novel approaches for the treatment of cancer.
The Company's first-in-class, proprietary technology, NanoXray, enhances
radiotherapy energy with a view to provide a new, more efficient treatment for
cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are
meant to treat potentially a wide variety of solid tumors including soft tissue
sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer,
glioblastoma, etc., via multiple routes of administration.
NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers,
prostate cancer, and liver cancers (primary and metastases). Additionally, head
and neck cancer and rectal cancer trials led by Nanobiotix's Taiwanese partner,
PharmaEngine, are underway in the Asia Pacific region. The Company has filed in
August 2016 for market approval (CE Marking) in Europe for its lead product
NBTXR3.
The Company started in 2016 a new preclinical research program in Immuno-
oncology with its lead product NBTXR3, which could have the potential to bring a
new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN:
FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company
Headquarter is based in Paris, France. Affiliate in Cambridge, United States.
Contact
-------------------------------------------------------------------------------
Nanobiotix
-------------------------------------------------------------------------------
Sarah Gaubert Noël Kurdi
Director, Communications & Public Director, Investor Relations
Affairs +1 (646) 241-4400
+33 (0)1 40 26 07 55 noel.kurdi(at)nanobiotix.com /
sarah.gaubert(at)nanobiotix.com / investors(at)nanobiotix.com
contact(at)nanobiotix.com
--------------------------------------
Media relations
-------------------------------------------------------------------------------
France - Springbok Consultants United States -
Marina Rosoff RooneyPartners
+33 (0)6 71 58 00 34 Marion Janic
marina(at)springbok.fr +1 (212) 223-4017
mjanic(at)rooneyco.com
Disclaimer
This press release contains certain forward-looking statements concerning
Nanobiotix and its business. Such forward-looking statements are based on
assumptions that Nanobiotix considers to be reasonable. However, there can be no
assurance that the estimates contained in such forward-looking statements will
be verified, which estimates are subject to numerous risks including the risks
set forth in the update of the reference document of Nanobiotix filed with the
French Financial Markets Authority (Autorité des Marchés Financiers) under
number D.16-0732-A01 on December 27, 2016 (a copy of which is available on
www.nanobiotix.com) and to the development of economic conditions, financial
markets and the markets in which Nanobiotix operates. The forward-looking
statements contained in this press release are also subject to risks not yet
known to Nanobiotix or not currently considered material by Nanobiotix. The
occurrence of all or part of such risks could cause actual results, financial
conditions, performance or achievements of Nanobiotix to be materially different
from such forward-looking statements.
This press release and the information that it contains do not constitute an
offer to sell or subscribe for, or a solicitation of an offer to purchase or
subscribe for, Nanobiotix shares in any country. At the moment NBTXR3 does not
bear a CE mark and is not permitted to be placed on the market or put into
service until NBTXR3 has obtained a CE mark.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NANOBIOTIX via GlobeNewswire
Datum: 15.06.2017 - 21:44 Uhr
Sprache: Deutsch
News-ID 548268
Anzahl Zeichen: 12637
contact information:
Town:
Paris
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 210 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NANOBIOTIX : new translational data presented at ASTRO, NCI AND SITC'S Immunotherapy Workshop"
steht unter der journalistisch-redaktionellen Verantwortung von
NANOBIOTIX (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
